# Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

> **NCT05389514** · — · TEMPORARILY_NOT_AVAILABLE · sponsor: **Providence Health & Services**

## Conditions studied

- KRAS G12V Mutant Advanced Epithelial Cancers

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Gemcitabine
- **DRUG:** Pembrolizumab
- **BIOLOGICAL:** Cell Infusion

## Key facts

- **NCT ID:** NCT05389514
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** TEMPORARILY_NOT_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05389514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05389514, "Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05389514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*